Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 203 | 2024 | 5462 | 14.500 |
Why?
|
Antibodies, Monoclonal | 99 | 2023 | 9274 | 5.530 |
Why?
|
Skin Neoplasms | 80 | 2023 | 5662 | 5.150 |
Why?
|
Immunotherapy | 68 | 2023 | 4414 | 4.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 59 | 2023 | 11472 | 3.340 |
Why?
|
Cancer Vaccines | 25 | 2023 | 1021 | 2.660 |
Why?
|
Antineoplastic Agents | 64 | 2023 | 13655 | 2.650 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 17 | 2023 | 902 | 2.560 |
Why?
|
Neoplasms | 68 | 2023 | 21596 | 2.080 |
Why?
|
Uveal Neoplasms | 7 | 2020 | 310 | 1.930 |
Why?
|
Mucous Membrane | 9 | 2021 | 670 | 1.700 |
Why?
|
Proto-Oncogene Proteins c-kit | 9 | 2017 | 774 | 1.680 |
Why?
|
Proto-Oncogene Proteins B-raf | 24 | 2021 | 2028 | 1.680 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 18 | 2020 | 1038 | 1.490 |
Why?
|
CD8-Positive T-Lymphocytes | 19 | 2021 | 4438 | 1.340 |
Why?
|
Tumor Microenvironment | 20 | 2023 | 3564 | 1.250 |
Why?
|
Indoles | 11 | 2019 | 1834 | 1.230 |
Why?
|
Vascular Endothelial Growth Factor A | 9 | 2024 | 3502 | 1.210 |
Why?
|
Immunomodulation | 5 | 2019 | 540 | 1.190 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 20 | 2023 | 5171 | 1.090 |
Why?
|
Antigens, CD | 13 | 2022 | 4024 | 1.070 |
Why?
|
Oncolytic Viruses | 3 | 2021 | 323 | 1.050 |
Why?
|
Pneumonia | 8 | 2021 | 2117 | 1.010 |
Why?
|
Mutation | 38 | 2023 | 29717 | 1.010 |
Why?
|
Pyrimidines | 6 | 2017 | 2933 | 1.000 |
Why?
|
Humans | 337 | 2024 | 742088 | 0.970 |
Why?
|
Neoplasm Metastasis | 30 | 2022 | 4839 | 0.970 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2018 | 434 | 0.900 |
Why?
|
Lung Neoplasms | 26 | 2023 | 13019 | 0.870 |
Why?
|
T-Lymphocytes, Cytotoxic | 7 | 2019 | 1820 | 0.870 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 664 | 0.850 |
Why?
|
Neoplasm Staging | 45 | 2022 | 11001 | 0.840 |
Why?
|
Carcinoma, Renal Cell | 14 | 2020 | 3123 | 0.820 |
Why?
|
Middle Aged | 149 | 2023 | 213127 | 0.810 |
Why?
|
Aged | 132 | 2022 | 162944 | 0.810 |
Why?
|
Disease-Free Survival | 28 | 2019 | 6891 | 0.770 |
Why?
|
Brain Neoplasms | 18 | 2021 | 8829 | 0.750 |
Why?
|
Triazoles | 2 | 2018 | 907 | 0.740 |
Why?
|
Aged, 80 and over | 67 | 2022 | 57683 | 0.730 |
Why?
|
Protein Kinase C | 3 | 2020 | 1227 | 0.720 |
Why?
|
Kaplan-Meier Estimate | 26 | 2019 | 6534 | 0.710 |
Why?
|
Antibodies, Neoplasm | 4 | 2016 | 286 | 0.710 |
Why?
|
Pyrroles | 3 | 2020 | 1143 | 0.710 |
Why?
|
Oncolytic Virotherapy | 4 | 2022 | 490 | 0.710 |
Why?
|
Treatment Outcome | 70 | 2021 | 62966 | 0.700 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2019 | 63 | 0.690 |
Why?
|
Antigens, Differentiation | 4 | 2008 | 926 | 0.690 |
Why?
|
Drug Resistance, Neoplasm | 12 | 2021 | 5163 | 0.680 |
Why?
|
Protein Kinase Inhibitors | 14 | 2019 | 5522 | 0.650 |
Why?
|
Male | 159 | 2023 | 349538 | 0.650 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2020 | 4379 | 0.650 |
Why?
|
Female | 167 | 2023 | 379592 | 0.640 |
Why?
|
Granuloma | 2 | 2018 | 315 | 0.640 |
Why?
|
Gene Expression Regulation, Neoplastic | 15 | 2021 | 8425 | 0.630 |
Why?
|
Vacuolar Proton-Translocating ATPases | 2 | 2014 | 195 | 0.630 |
Why?
|
Sarcoidosis, Pulmonary | 1 | 2018 | 43 | 0.630 |
Why?
|
Antibodies, Blocking | 4 | 2019 | 254 | 0.610 |
Why?
|
Lymphoma | 5 | 2022 | 1873 | 0.600 |
Why?
|
Clinical Trials as Topic | 22 | 2023 | 7901 | 0.600 |
Why?
|
Antigens, Neoplasm | 14 | 2021 | 1983 | 0.600 |
Why?
|
Piperazines | 4 | 2014 | 2488 | 0.580 |
Why?
|
Angiopoietin-2 | 2 | 2016 | 170 | 0.560 |
Why?
|
Colitis | 7 | 2022 | 1149 | 0.560 |
Why?
|
Adult | 107 | 2023 | 213712 | 0.550 |
Why?
|
Molecular Targeted Therapy | 14 | 2021 | 2723 | 0.550 |
Why?
|
Galectin 1 | 1 | 2017 | 131 | 0.550 |
Why?
|
Leukocytes, Mononuclear | 10 | 2024 | 1835 | 0.540 |
Why?
|
Herpesvirus 1, Human | 3 | 2022 | 742 | 0.540 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2021 | 789 | 0.530 |
Why?
|
Drug Administration Schedule | 17 | 2021 | 4929 | 0.520 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2019 | 880 | 0.520 |
Why?
|
Recombinant Fusion Proteins | 1 | 2024 | 3770 | 0.510 |
Why?
|
Sulfonamides | 7 | 2014 | 1932 | 0.510 |
Why?
|
GTP-Binding Protein alpha Subunits | 2 | 2012 | 100 | 0.500 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 4 | 2021 | 647 | 0.500 |
Why?
|
Benzamides | 4 | 2014 | 1378 | 0.500 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2018 | 265 | 0.490 |
Why?
|
Combined Modality Therapy | 13 | 2022 | 8621 | 0.490 |
Why?
|
Neovascularization, Pathologic | 5 | 2019 | 2633 | 0.480 |
Why?
|
Killer Cells, Natural | 4 | 2023 | 2133 | 0.480 |
Why?
|
Kidney Neoplasms | 10 | 2020 | 4229 | 0.460 |
Why?
|
Survival Rate | 22 | 2021 | 12773 | 0.460 |
Why?
|
Hydroxamic Acids | 1 | 2016 | 495 | 0.460 |
Why?
|
HLA Antigens | 2 | 2018 | 1382 | 0.450 |
Why?
|
MAP Kinase Kinase Kinases | 5 | 2019 | 261 | 0.450 |
Why?
|
Drug Synergism | 3 | 2016 | 1791 | 0.450 |
Why?
|
Clinical Trials, Phase II as Topic | 8 | 2019 | 627 | 0.450 |
Why?
|
Disease Progression | 23 | 2022 | 13256 | 0.450 |
Why?
|
T-Lymphocytes | 15 | 2023 | 10163 | 0.440 |
Why?
|
Inhibitor of Apoptosis Proteins | 4 | 2016 | 215 | 0.440 |
Why?
|
Radiotherapy | 2 | 2019 | 1525 | 0.440 |
Why?
|
Prognosis | 29 | 2021 | 29010 | 0.420 |
Why?
|
Cell Line, Tumor | 23 | 2020 | 16665 | 0.420 |
Why?
|
T-Lymphocytes, Regulatory | 9 | 2020 | 2986 | 0.420 |
Why?
|
Immunity, Humoral | 5 | 2019 | 596 | 0.420 |
Why?
|
Ovarian Neoplasms | 5 | 2020 | 4823 | 0.400 |
Why?
|
Immunity, Cellular | 3 | 2016 | 1606 | 0.400 |
Why?
|
Sunlight | 1 | 2013 | 325 | 0.400 |
Why?
|
Neoplasm Proteins | 8 | 2021 | 3691 | 0.400 |
Why?
|
Dose-Response Relationship, Drug | 19 | 2021 | 10943 | 0.390 |
Why?
|
Hepatitis | 3 | 2023 | 227 | 0.390 |
Why?
|
Immunophenotyping | 7 | 2022 | 1866 | 0.390 |
Why?
|
Thyroid Diseases | 3 | 2019 | 378 | 0.380 |
Why?
|
Cell Proliferation | 9 | 2021 | 10472 | 0.380 |
Why?
|
Quinazolines | 2 | 2020 | 1355 | 0.380 |
Why?
|
Cytokines | 11 | 2022 | 7317 | 0.350 |
Why?
|
Melanoma, Experimental | 4 | 2019 | 559 | 0.350 |
Why?
|
Peptide Fragments | 3 | 2019 | 5095 | 0.340 |
Why?
|
Medical Oncology | 4 | 2023 | 2235 | 0.330 |
Why?
|
Apoptosis | 8 | 2021 | 9715 | 0.330 |
Why?
|
Tumor Burden | 8 | 2022 | 1905 | 0.330 |
Why?
|
T-Lymphocyte Subsets | 6 | 2019 | 1837 | 0.330 |
Why?
|
Gene Amplification | 1 | 2013 | 1062 | 0.330 |
Why?
|
Antibody Formation | 5 | 2016 | 1402 | 0.320 |
Why?
|
Tumor Escape | 3 | 2021 | 349 | 0.320 |
Why?
|
Maximum Tolerated Dose | 10 | 2022 | 891 | 0.320 |
Why?
|
Imidazoles | 6 | 2019 | 1205 | 0.310 |
Why?
|
Survival Analysis | 15 | 2020 | 10248 | 0.310 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2012 | 578 | 0.310 |
Why?
|
MAP Kinase Signaling System | 2 | 2012 | 1525 | 0.310 |
Why?
|
Double-Blind Method | 11 | 2022 | 12017 | 0.300 |
Why?
|
Diagnostic Imaging | 2 | 2018 | 3507 | 0.300 |
Why?
|
Autoimmunity | 3 | 2018 | 1348 | 0.290 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2023 | 5425 | 0.290 |
Why?
|
Tomography, X-Ray Computed | 14 | 2019 | 20086 | 0.280 |
Why?
|
Adrenal Cortex Hormones | 5 | 2021 | 1847 | 0.280 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 4 | 2013 | 625 | 0.280 |
Why?
|
Amino Acid Sequence | 4 | 2021 | 13814 | 0.270 |
Why?
|
Hematologic Neoplasms | 2 | 2016 | 1820 | 0.270 |
Why?
|
Tumor Cells, Cultured | 9 | 2021 | 6313 | 0.270 |
Why?
|
Follow-Up Studies | 21 | 2021 | 39004 | 0.270 |
Why?
|
Clinical Trials, Phase III as Topic | 7 | 2018 | 839 | 0.270 |
Why?
|
Oximes | 4 | 2019 | 309 | 0.270 |
Why?
|
Adjuvants, Immunologic | 3 | 2022 | 1000 | 0.270 |
Why?
|
Endocrine System Diseases | 2 | 2018 | 248 | 0.260 |
Why?
|
Immunization, Passive | 1 | 2008 | 625 | 0.260 |
Why?
|
Cell Adhesion Molecules | 2 | 2023 | 1599 | 0.260 |
Why?
|
Gene Expression Profiling | 13 | 2021 | 9410 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2022 | 9185 | 0.240 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2938 | 0.240 |
Why?
|
North America | 2 | 2021 | 1249 | 0.240 |
Why?
|
Rectal Neoplasms | 2 | 2016 | 1195 | 0.240 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2012 | 2014 | 0.240 |
Why?
|
Autoantigens | 1 | 2008 | 891 | 0.230 |
Why?
|
Immunologic Factors | 3 | 2021 | 1575 | 0.230 |
Why?
|
Young Adult | 25 | 2021 | 56350 | 0.230 |
Why?
|
Animals | 46 | 2022 | 168561 | 0.230 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2023 | 1368 | 0.230 |
Why?
|
Immunohistochemistry | 12 | 2019 | 11363 | 0.230 |
Why?
|
NF-kappa B | 1 | 2012 | 2500 | 0.230 |
Why?
|
Hypothyroidism | 3 | 2019 | 659 | 0.230 |
Why?
|
Immunosuppressive Agents | 4 | 2021 | 4147 | 0.220 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2021 | 370 | 0.220 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2011 | 2915 | 0.220 |
Why?
|
Tobacco, Smokeless | 1 | 2023 | 129 | 0.220 |
Why?
|
Lymphocytes | 4 | 2020 | 2614 | 0.210 |
Why?
|
Leukemia, Myeloid, Acute | 3 | 2023 | 3497 | 0.210 |
Why?
|
Urologic Neoplasms | 2 | 2018 | 316 | 0.210 |
Why?
|
Flow Cytometry | 7 | 2023 | 5975 | 0.210 |
Why?
|
Retrospective Studies | 34 | 2023 | 77098 | 0.210 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2022 | 798 | 0.210 |
Why?
|
Immune Tolerance | 3 | 2011 | 2257 | 0.210 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2018 | 319 | 0.210 |
Why?
|
Interferon Regulatory Factor-1 | 1 | 2021 | 68 | 0.200 |
Why?
|
SOXE Transcription Factors | 1 | 2021 | 57 | 0.200 |
Why?
|
Thyrotoxicosis | 2 | 2019 | 82 | 0.200 |
Why?
|
Enterocolitis | 1 | 2022 | 102 | 0.200 |
Why?
|
Lymphadenitis | 1 | 2022 | 98 | 0.200 |
Why?
|
Carcinoma | 2 | 2016 | 2374 | 0.200 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2012 | 140 | 0.200 |
Why?
|
Leukoplakia, Oral | 1 | 2021 | 73 | 0.200 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 147 | 0.190 |
Why?
|
Cohort Studies | 18 | 2021 | 40450 | 0.190 |
Why?
|
Histocompatibility Antigens Class I | 5 | 2021 | 1366 | 0.190 |
Why?
|
Gastritis | 1 | 2022 | 191 | 0.190 |
Why?
|
Injections, Intralesional | 1 | 2021 | 276 | 0.190 |
Why?
|
Histiocytes | 1 | 2021 | 103 | 0.190 |
Why?
|
Monitoring, Immunologic | 1 | 2021 | 100 | 0.190 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 1377 | 0.190 |
Why?
|
Epitopes | 4 | 2021 | 2569 | 0.190 |
Why?
|
Splenic Neoplasms | 1 | 2021 | 100 | 0.190 |
Why?
|
Recombinant Proteins | 7 | 2018 | 6608 | 0.190 |
Why?
|
Pyrimidinones | 4 | 2019 | 370 | 0.180 |
Why?
|
Methylprednisolone | 1 | 2021 | 388 | 0.180 |
Why?
|
Primary Myelofibrosis | 1 | 2022 | 214 | 0.180 |
Why?
|
Interferon Regulatory Factors | 1 | 2021 | 270 | 0.180 |
Why?
|
GTP Phosphohydrolases | 2 | 2013 | 508 | 0.180 |
Why?
|
Immune System Diseases | 1 | 2022 | 262 | 0.180 |
Why?
|
Endogenous Retroviruses | 1 | 2020 | 112 | 0.180 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2021 | 180 | 0.170 |
Why?
|
Immunotherapy, Adoptive | 4 | 2020 | 1255 | 0.170 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2012 | 731 | 0.170 |
Why?
|
Colitis, Microscopic | 1 | 2020 | 77 | 0.170 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2019 | 130 | 0.170 |
Why?
|
Alanine Transaminase | 1 | 2021 | 592 | 0.170 |
Why?
|
Addison Disease | 1 | 2019 | 48 | 0.160 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2020 | 4029 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2021 | 9941 | 0.160 |
Why?
|
Antibodies, Bispecific | 1 | 2021 | 164 | 0.160 |
Why?
|
Calcium-Binding Proteins | 1 | 2023 | 1081 | 0.160 |
Why?
|
Microsatellite Repeats | 2 | 2018 | 800 | 0.160 |
Why?
|
Pruritus | 2 | 2019 | 359 | 0.160 |
Why?
|
Drug Monitoring | 3 | 2021 | 956 | 0.160 |
Why?
|
Myeloid Cells | 2 | 2020 | 804 | 0.160 |
Why?
|
Time Factors | 15 | 2021 | 40054 | 0.160 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 109 | 0.160 |
Why?
|
Pancreatitis | 2 | 2023 | 1090 | 0.160 |
Why?
|
Enzyme Activation | 3 | 2015 | 3701 | 0.160 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 704 | 0.160 |
Why?
|
Pyridones | 4 | 2019 | 712 | 0.160 |
Why?
|
Antigens, CD19 | 1 | 2020 | 379 | 0.150 |
Why?
|
Reed-Sternberg Cells | 1 | 2017 | 73 | 0.150 |
Why?
|
Membrane Glycoproteins | 4 | 2016 | 3769 | 0.150 |
Why?
|
Lymphocyte Activation | 4 | 2019 | 5519 | 0.150 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2021 | 651 | 0.150 |
Why?
|
Colonic Neoplasms | 2 | 2022 | 2542 | 0.150 |
Why?
|
Retreatment | 2 | 2016 | 604 | 0.150 |
Why?
|
Melanoma-Specific Antigens | 2 | 2018 | 80 | 0.150 |
Why?
|
Cryopreservation | 1 | 2022 | 664 | 0.150 |
Why?
|
Bone Marrow Cells | 3 | 2022 | 2513 | 0.150 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2021 | 2524 | 0.150 |
Why?
|
Skin | 3 | 2019 | 4353 | 0.150 |
Why?
|
Isoenzymes | 2 | 2012 | 1725 | 0.150 |
Why?
|
Radiotherapy Dosage | 2 | 2022 | 2876 | 0.150 |
Why?
|
4-1BB Ligand | 1 | 2016 | 29 | 0.150 |
Why?
|
Receptors, Chemokine | 1 | 2020 | 669 | 0.150 |
Why?
|
Viral Envelope Proteins | 1 | 2020 | 635 | 0.150 |
Why?
|
Cell Separation | 3 | 2018 | 1749 | 0.150 |
Why?
|
Fatigue | 3 | 2019 | 1526 | 0.140 |
Why?
|
Signal Transduction | 5 | 2019 | 23387 | 0.140 |
Why?
|
Neoplasm Invasiveness | 5 | 2017 | 3612 | 0.140 |
Why?
|
Interferon-gamma | 4 | 2020 | 3199 | 0.140 |
Why?
|
Histiocytic Necrotizing Lymphadenitis | 1 | 2016 | 23 | 0.140 |
Why?
|
Lymphopenia | 1 | 2018 | 285 | 0.140 |
Why?
|
Chemokines | 2 | 2020 | 954 | 0.140 |
Why?
|
Creatinine | 2 | 2019 | 1916 | 0.140 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 322 | 0.140 |
Why?
|
Histiocytosis, Sinus | 1 | 2016 | 47 | 0.140 |
Why?
|
Mice | 23 | 2022 | 81045 | 0.140 |
Why?
|
Calcifediol | 1 | 2017 | 166 | 0.140 |
Why?
|
Intestinal Neoplasms | 1 | 2018 | 319 | 0.140 |
Why?
|
Dacarbazine | 2 | 2017 | 567 | 0.140 |
Why?
|
Staining and Labeling | 4 | 2022 | 1099 | 0.130 |
Why?
|
Angiotensin II | 1 | 2019 | 881 | 0.130 |
Why?
|
Quality Control | 1 | 2018 | 841 | 0.130 |
Why?
|
Complementarity Determining Regions | 1 | 2016 | 149 | 0.130 |
Why?
|
Single-Cell Analysis | 3 | 2021 | 2183 | 0.130 |
Why?
|
Neoplasms, Unknown Primary | 2 | 2008 | 104 | 0.130 |
Why?
|
Genes, cdc | 1 | 2016 | 116 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2003 | 897 | 0.130 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 2006 | 0.130 |
Why?
|
PTEN Phosphohydrolase | 2 | 2020 | 1144 | 0.130 |
Why?
|
Chemokine CXCL10 | 1 | 2016 | 304 | 0.130 |
Why?
|
Cell Movement | 4 | 2016 | 5212 | 0.130 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2015 | 41 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 535 | 0.130 |
Why?
|
Janus Kinase 3 | 1 | 2015 | 78 | 0.130 |
Why?
|
Niacinamide | 2 | 2015 | 416 | 0.130 |
Why?
|
Nephritis, Interstitial | 1 | 2016 | 156 | 0.130 |
Why?
|
Chemokine CX3CL1 | 1 | 2014 | 58 | 0.130 |
Why?
|
Bone Marrow | 2 | 2022 | 2941 | 0.130 |
Why?
|
Endpoint Determination | 1 | 2018 | 600 | 0.120 |
Why?
|
Cell Survival | 3 | 2018 | 5872 | 0.120 |
Why?
|
Central Nervous System | 2 | 2015 | 1354 | 0.120 |
Why?
|
Sarcoma, Clear Cell | 1 | 2015 | 76 | 0.120 |
Why?
|
Thrombotic Microangiopathies | 1 | 2016 | 132 | 0.120 |
Why?
|
DNA, Bacterial | 2 | 2017 | 1465 | 0.120 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 944 | 0.120 |
Why?
|
Prednisone | 1 | 2019 | 1567 | 0.120 |
Why?
|
Oxidoreductases | 1 | 2016 | 424 | 0.120 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2016 | 171 | 0.120 |
Why?
|
Fever | 2 | 2019 | 1612 | 0.120 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 3 | 2016 | 1683 | 0.120 |
Why?
|
Phenylurea Compounds | 2 | 2015 | 526 | 0.120 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1052 | 0.120 |
Why?
|
Exons | 2 | 2017 | 2431 | 0.120 |
Why?
|
Antigen-Presenting Cells | 3 | 2022 | 969 | 0.120 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2016 | 252 | 0.120 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2016 | 707 | 0.120 |
Why?
|
Drug Evaluation | 1 | 2015 | 637 | 0.120 |
Why?
|
Pituitary Diseases | 1 | 2014 | 141 | 0.120 |
Why?
|
Natural Killer T-Cells | 1 | 2017 | 315 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2013 | 2502 | 0.120 |
Why?
|
Immunotherapy, Active | 2 | 2010 | 60 | 0.120 |
Why?
|
Esophageal Neoplasms | 1 | 2023 | 1581 | 0.110 |
Why?
|
Protein Isoforms | 2 | 2017 | 1727 | 0.110 |
Why?
|
Encephalitis | 1 | 2017 | 423 | 0.110 |
Why?
|
Interferon-alpha | 4 | 2022 | 895 | 0.110 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2018 | 2638 | 0.110 |
Why?
|
Lymphocyte Count | 4 | 2018 | 792 | 0.110 |
Why?
|
HLA-A2 Antigen | 2 | 2011 | 213 | 0.110 |
Why?
|
Biological Specimen Banks | 1 | 2018 | 707 | 0.110 |
Why?
|
Vulvar Neoplasms | 1 | 2016 | 272 | 0.110 |
Why?
|
Genomics | 5 | 2022 | 5692 | 0.110 |
Why?
|
Neutrophil Infiltration | 1 | 2016 | 390 | 0.110 |
Why?
|
Germ-Line Mutation | 2 | 2018 | 1786 | 0.110 |
Why?
|
Immediate-Early Proteins | 1 | 2016 | 453 | 0.110 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1596 | 0.110 |
Why?
|
Drug Therapy, Combination | 6 | 2021 | 6483 | 0.110 |
Why?
|
Myelodysplastic Syndromes | 1 | 2023 | 1351 | 0.110 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 2015 | 799 | 0.110 |
Why?
|
Mass Spectrometry | 1 | 2020 | 2203 | 0.110 |
Why?
|
Lymphocyte Transfusion | 1 | 2013 | 235 | 0.110 |
Why?
|
Leiomyosarcoma | 1 | 2017 | 477 | 0.110 |
Why?
|
Adolescent | 14 | 2021 | 85649 | 0.110 |
Why?
|
Drug Eruptions | 2 | 2014 | 295 | 0.110 |
Why?
|
Quality of Life | 3 | 2022 | 12730 | 0.110 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 7 | 2015 | 3862 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1265 | 0.110 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2016 | 1155 | 0.110 |
Why?
|
Neuroendocrine Tumors | 1 | 2018 | 594 | 0.110 |
Why?
|
DNA Mutational Analysis | 2 | 2014 | 4187 | 0.110 |
Why?
|
Rhabdomyolysis | 1 | 2013 | 150 | 0.110 |
Why?
|
Carboplatin | 4 | 2018 | 799 | 0.110 |
Why?
|
Ribosomal Protein S6 Kinases | 1 | 2012 | 205 | 0.110 |
Why?
|
Keratoacanthoma | 1 | 2012 | 32 | 0.100 |
Why?
|
Intestine, Small | 1 | 2018 | 1243 | 0.100 |
Why?
|
Angiogenesis Inhibitors | 2 | 2019 | 2038 | 0.100 |
Why?
|
Eye Neoplasms | 1 | 2014 | 313 | 0.100 |
Why?
|
Inhibitory Concentration 50 | 1 | 2013 | 459 | 0.100 |
Why?
|
Diarrhea | 4 | 2023 | 1343 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2012 | 286 | 0.100 |
Why?
|
Models, Biological | 3 | 2013 | 9581 | 0.100 |
Why?
|
Lymphocyte Depletion | 1 | 2013 | 608 | 0.100 |
Why?
|
Pleural Neoplasms | 1 | 2016 | 607 | 0.100 |
Why?
|
Research Design | 3 | 2019 | 5979 | 0.100 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 713 | 0.100 |
Why?
|
Bromodeoxyuridine | 1 | 2012 | 322 | 0.100 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2885 | 0.100 |
Why?
|
Smoking Cessation | 1 | 2023 | 2068 | 0.100 |
Why?
|
Phosphorylation | 2 | 2013 | 8436 | 0.100 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2018 | 933 | 0.100 |
Why?
|
Interleukin-2 | 4 | 2017 | 1887 | 0.100 |
Why?
|
Cell Nucleus | 1 | 2020 | 2968 | 0.100 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 322 | 0.100 |
Why?
|
Stromal Cells | 1 | 2016 | 1353 | 0.100 |
Why?
|
Adaptive Immunity | 1 | 2016 | 712 | 0.100 |
Why?
|
Endothelial Cells | 1 | 2023 | 3455 | 0.090 |
Why?
|
Comparative Genomic Hybridization | 1 | 2012 | 496 | 0.090 |
Why?
|
Sarcoidosis | 1 | 2016 | 503 | 0.090 |
Why?
|
Colorectal Neoplasms | 3 | 2021 | 6754 | 0.090 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 390 | 0.090 |
Why?
|
Mesothelioma | 1 | 2016 | 818 | 0.090 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1889 | 0.090 |
Why?
|
Cyclin D1 | 1 | 2012 | 462 | 0.090 |
Why?
|
Practice Guidelines as Topic | 3 | 2018 | 7276 | 0.090 |
Why?
|
Biopsy | 4 | 2019 | 6756 | 0.090 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2022 | 2229 | 0.090 |
Why?
|
Cell Adhesion | 1 | 2016 | 3139 | 0.090 |
Why?
|
ras Proteins | 1 | 2015 | 1060 | 0.090 |
Why?
|
Patient Selection | 2 | 2021 | 4214 | 0.090 |
Why?
|
Hodgkin Disease | 1 | 2017 | 1413 | 0.090 |
Why?
|
Immunoblotting | 1 | 2013 | 1683 | 0.090 |
Why?
|
Graft vs Host Disease | 1 | 2022 | 2951 | 0.090 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2015 | 2013 | 0.090 |
Why?
|
Colonoscopy | 1 | 2017 | 1365 | 0.080 |
Why?
|
Cells, Cultured | 2 | 2019 | 19223 | 0.080 |
Why?
|
Cell Membrane | 2 | 2015 | 3744 | 0.080 |
Why?
|
Mice, Inbred C57BL | 7 | 2021 | 21821 | 0.080 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 689 | 0.080 |
Why?
|
Viral Proteins | 1 | 2016 | 1899 | 0.080 |
Why?
|
Clinical Protocols | 1 | 2014 | 1459 | 0.080 |
Why?
|
Immunologic Memory | 2 | 2015 | 1348 | 0.080 |
Why?
|
STAT3 Transcription Factor | 1 | 2012 | 874 | 0.080 |
Why?
|
Stem Cells | 1 | 2021 | 3563 | 0.080 |
Why?
|
Immunity, Innate | 2 | 2018 | 2956 | 0.080 |
Why?
|
Neoplasm Seeding | 1 | 2008 | 87 | 0.080 |
Why?
|
Receptors, Immunologic | 3 | 2023 | 1423 | 0.080 |
Why?
|
Endocrine Glands | 2 | 2018 | 103 | 0.080 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2014 | 806 | 0.080 |
Why?
|
Uterine Neoplasms | 1 | 2017 | 1513 | 0.080 |
Why?
|
Immune System | 1 | 2013 | 804 | 0.070 |
Why?
|
Proportional Hazards Models | 5 | 2021 | 12344 | 0.070 |
Why?
|
Pyridines | 2 | 2017 | 2818 | 0.070 |
Why?
|
Vitamin D Deficiency | 1 | 2017 | 1331 | 0.070 |
Why?
|
Up-Regulation | 1 | 2016 | 4211 | 0.070 |
Why?
|
Autoantibodies | 2 | 2008 | 2036 | 0.070 |
Why?
|
Antibodies | 3 | 2020 | 2459 | 0.070 |
Why?
|
Gene Expression | 3 | 2019 | 7790 | 0.070 |
Why?
|
Central Nervous System Neoplasms | 1 | 2015 | 895 | 0.070 |
Why?
|
Positron-Emission Tomography | 4 | 2015 | 6259 | 0.070 |
Why?
|
Pathology | 1 | 2009 | 272 | 0.070 |
Why?
|
Nervous System Diseases | 1 | 2017 | 1617 | 0.070 |
Why?
|
Vitamin D | 1 | 2020 | 3211 | 0.070 |
Why?
|
Gastroenteritis | 1 | 2008 | 245 | 0.070 |
Why?
|
United States | 9 | 2023 | 69693 | 0.070 |
Why?
|
Coculture Techniques | 2 | 2023 | 1341 | 0.070 |
Why?
|
Melanocytes | 1 | 2009 | 515 | 0.070 |
Why?
|
Disease Management | 4 | 2021 | 2450 | 0.070 |
Why?
|
Macrophages | 3 | 2017 | 5655 | 0.070 |
Why?
|
Immunocompetence | 2 | 2018 | 137 | 0.070 |
Why?
|
Protein Array Analysis | 1 | 2008 | 411 | 0.070 |
Why?
|
Membrane Proteins | 2 | 2013 | 7873 | 0.070 |
Why?
|
Inflammation | 2 | 2023 | 10578 | 0.070 |
Why?
|
Terminology as Topic | 1 | 2013 | 1548 | 0.070 |
Why?
|
Radiography | 3 | 2015 | 7010 | 0.070 |
Why?
|
Genes, ras | 1 | 2008 | 691 | 0.070 |
Why?
|
Fusobacterium nucleatum | 2 | 2017 | 160 | 0.070 |
Why?
|
Photochemotherapy | 1 | 2012 | 804 | 0.070 |
Why?
|
Biomimetics | 1 | 2007 | 172 | 0.070 |
Why?
|
Kidney Transplantation | 1 | 2020 | 4246 | 0.070 |
Why?
|
Cell Cycle Proteins | 2 | 2016 | 3444 | 0.070 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2020 | 2410 | 0.070 |
Why?
|
Biomedical Research | 2 | 2012 | 3306 | 0.070 |
Why?
|
Down-Regulation | 1 | 2013 | 3001 | 0.070 |
Why?
|
Soft Tissue Neoplasms | 1 | 2015 | 1361 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2019 | 3471 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4751 | 0.060 |
Why?
|
Gastric Mucosa | 1 | 2008 | 598 | 0.060 |
Why?
|
Hepatocytes | 1 | 2012 | 1209 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2015 | 5062 | 0.060 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2006 | 304 | 0.060 |
Why?
|
Blotting, Western | 2 | 2013 | 5180 | 0.060 |
Why?
|
Recurrence | 4 | 2023 | 8333 | 0.060 |
Why?
|
Algorithms | 4 | 2020 | 13853 | 0.060 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 3639 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2016 | 4414 | 0.060 |
Why?
|
Antigen Presentation | 3 | 2008 | 1284 | 0.060 |
Why?
|
Lymphatic Metastasis | 5 | 2015 | 2906 | 0.060 |
Why?
|
Drug Design | 1 | 2010 | 1078 | 0.060 |
Why?
|
Anastomosis, Surgical | 1 | 2008 | 985 | 0.060 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 2658 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2019 | 3336 | 0.060 |
Why?
|
Ligands | 3 | 2018 | 3293 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2018 | 7721 | 0.060 |
Why?
|
Protein Processing, Post-Translational | 1 | 2012 | 1989 | 0.060 |
Why?
|
Intention to Treat Analysis | 2 | 2015 | 425 | 0.060 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 2 | 2019 | 804 | 0.060 |
Why?
|
Prospective Studies | 6 | 2021 | 53187 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2016 | 2011 | 0.060 |
Why?
|
Acute Kidney Injury | 1 | 2016 | 1967 | 0.060 |
Why?
|
Head and Neck Neoplasms | 2 | 2016 | 2712 | 0.060 |
Why?
|
Radioimmunotherapy | 1 | 2023 | 79 | 0.060 |
Why?
|
MART-1 Antigen | 3 | 2011 | 64 | 0.060 |
Why?
|
Autoimmune Diseases | 1 | 2015 | 2130 | 0.060 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 2 | 2018 | 91 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2012 | 2107 | 0.060 |
Why?
|
Anemia, Aplastic | 1 | 2005 | 226 | 0.060 |
Why?
|
Repetitive Sequences, Amino Acid | 1 | 2003 | 95 | 0.060 |
Why?
|
Cranial Irradiation | 2 | 2017 | 401 | 0.060 |
Why?
|
Guidelines as Topic | 1 | 2009 | 1402 | 0.050 |
Why?
|
Remission Induction | 2 | 2005 | 2384 | 0.050 |
Why?
|
Receptors, Opioid | 1 | 2003 | 155 | 0.050 |
Why?
|
AMP-Activated Protein Kinases | 2 | 2016 | 608 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 4553 | 0.050 |
Why?
|
Cyclosporine | 1 | 2005 | 784 | 0.050 |
Why?
|
Hypopigmentation | 1 | 2002 | 41 | 0.050 |
Why?
|
Azathioprine | 1 | 2023 | 355 | 0.050 |
Why?
|
Drug Prescriptions | 1 | 1991 | 1636 | 0.050 |
Why?
|
Molecular Sequence Data | 3 | 2012 | 18112 | 0.050 |
Why?
|
Necrosis | 2 | 2003 | 1643 | 0.050 |
Why?
|
Adoptive Transfer | 2 | 2017 | 844 | 0.050 |
Why?
|
Neoplastic Stem Cells | 1 | 2010 | 1376 | 0.050 |
Why?
|
Paclitaxel | 2 | 2015 | 1707 | 0.050 |
Why?
|
Italy | 2 | 2014 | 828 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15530 | 0.050 |
Why?
|
Tacrolimus | 1 | 2005 | 741 | 0.050 |
Why?
|
Receptors, CCR6 | 1 | 2021 | 80 | 0.050 |
Why?
|
Peptide Library | 1 | 2002 | 350 | 0.050 |
Why?
|
Models, Statistical | 2 | 2013 | 5100 | 0.050 |
Why?
|
Fluorescent Antibody Technique | 2 | 2017 | 2505 | 0.050 |
Why?
|
Oncogenes | 1 | 2007 | 1263 | 0.050 |
Why?
|
gp100 Melanoma Antigen | 3 | 2006 | 39 | 0.050 |
Why?
|
Immunity | 2 | 2018 | 1011 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5249 | 0.050 |
Why?
|
Nausea | 1 | 2023 | 665 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2021 | 4771 | 0.050 |
Why?
|
Tissue Distribution | 3 | 2020 | 2335 | 0.050 |
Why?
|
Glioblastoma | 1 | 2015 | 3456 | 0.050 |
Why?
|
Glucocorticoids | 2 | 2022 | 2107 | 0.050 |
Why?
|
Liver Function Tests | 1 | 2021 | 528 | 0.050 |
Why?
|
Glioma | 1 | 2015 | 3388 | 0.050 |
Why?
|
Callitrichinae | 2 | 1990 | 23 | 0.040 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2021 | 279 | 0.040 |
Why?
|
Freezing | 1 | 2020 | 303 | 0.040 |
Why?
|
Vaccination | 2 | 2022 | 3256 | 0.040 |
Why?
|
Mice, Congenic | 1 | 2019 | 99 | 0.040 |
Why?
|
Receptors, CXCR3 | 1 | 2020 | 237 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2020 | 14554 | 0.040 |
Why?
|
Radiosurgery | 1 | 2008 | 1309 | 0.040 |
Why?
|
RNA, Double-Stranded | 1 | 2020 | 289 | 0.040 |
Why?
|
Interleukin-15 | 2 | 2011 | 184 | 0.040 |
Why?
|
Lymphocytic Choriomeningitis | 1 | 2019 | 132 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2017 | 2271 | 0.040 |
Why?
|
Liver Neoplasms | 2 | 2012 | 4249 | 0.040 |
Why?
|
Lymphocytic choriomeningitis virus | 1 | 2019 | 168 | 0.040 |
Why?
|
Chronic Disease | 1 | 2013 | 9144 | 0.040 |
Why?
|
Gene Dosage | 2 | 2016 | 1251 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 902 | 0.040 |
Why?
|
Azetidines | 1 | 2019 | 142 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2021 | 705 | 0.040 |
Why?
|
Lymphocyte Subsets | 1 | 2019 | 315 | 0.040 |
Why?
|
Sirolimus | 1 | 2005 | 1562 | 0.040 |
Why?
|
Genes, p16 | 1 | 1998 | 157 | 0.040 |
Why?
|
Filtration | 1 | 2018 | 234 | 0.040 |
Why?
|
Base Sequence | 1 | 2008 | 12797 | 0.040 |
Why?
|
Intestinal Mucosa | 1 | 2008 | 3038 | 0.040 |
Why?
|
Adenosine Triphosphate | 1 | 2023 | 2024 | 0.040 |
Why?
|
Herpesviridae | 1 | 2017 | 109 | 0.040 |
Why?
|
Multigene Family | 1 | 2020 | 1102 | 0.040 |
Why?
|
Neutrophils | 2 | 2020 | 3711 | 0.040 |
Why?
|
Galactosylceramides | 1 | 2017 | 92 | 0.040 |
Why?
|
Genes, MHC Class I | 2 | 2006 | 258 | 0.040 |
Why?
|
New Zealand | 1 | 2017 | 357 | 0.040 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 195 | 0.040 |
Why?
|
Neoplasms, Experimental | 1 | 2002 | 1274 | 0.040 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2020 | 1723 | 0.040 |
Why?
|
Peptides | 3 | 2021 | 4392 | 0.040 |
Why?
|
Obesity | 1 | 2019 | 12705 | 0.040 |
Why?
|
Dendritic Cells | 2 | 2005 | 2723 | 0.040 |
Why?
|
Gastrointestinal Diseases | 2 | 2016 | 1167 | 0.030 |
Why?
|
Tissue Embedding | 1 | 2015 | 43 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2022 | 1059 | 0.030 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1998 | 537 | 0.030 |
Why?
|
Odds Ratio | 2 | 2019 | 9846 | 0.030 |
Why?
|
Cognition | 1 | 2013 | 6722 | 0.030 |
Why?
|
Data Mining | 1 | 2021 | 537 | 0.030 |
Why?
|
Cluster Analysis | 2 | 2016 | 2713 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2020 | 1342 | 0.030 |
Why?
|
Drug Combinations | 1 | 2021 | 1961 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2013 | 701 | 0.030 |
Why?
|
Risk Assessment | 4 | 2021 | 23320 | 0.030 |
Why?
|
Drug Resistance | 1 | 2021 | 1608 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2017 | 351 | 0.030 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 1998 | 657 | 0.030 |
Why?
|
Incidence | 3 | 2019 | 20928 | 0.030 |
Why?
|
Fibrosis | 1 | 2022 | 2026 | 0.030 |
Why?
|
Forkhead Transcription Factors | 2 | 2016 | 1613 | 0.030 |
Why?
|
Culture Media, Conditioned | 1 | 2016 | 533 | 0.030 |
Why?
|
Dermatitis | 1 | 2017 | 197 | 0.030 |
Why?
|
Drug Substitution | 1 | 2017 | 281 | 0.030 |
Why?
|
Prednisolone | 1 | 2016 | 333 | 0.030 |
Why?
|
Thyroiditis | 1 | 2015 | 85 | 0.030 |
Why?
|
Receptors, IgG | 1 | 2018 | 582 | 0.030 |
Why?
|
DNA Helicases | 1 | 2020 | 861 | 0.030 |
Why?
|
Cell Count | 1 | 2018 | 1831 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 1998 | 670 | 0.030 |
Why?
|
Drug Delivery Systems | 1 | 2006 | 2217 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2019 | 974 | 0.030 |
Why?
|
Transplantation Immunology | 1 | 2016 | 547 | 0.030 |
Why?
|
Australia | 1 | 2017 | 1167 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 683 | 0.030 |
Why?
|
New England | 1 | 2017 | 1021 | 0.030 |
Why?
|
HeLa Cells | 1 | 2020 | 3127 | 0.030 |
Why?
|
Receptors, Death Domain | 1 | 2013 | 32 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2016 | 3585 | 0.030 |
Why?
|
Lymphatic Diseases | 1 | 2015 | 324 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3689 | 0.030 |
Why?
|
Disease Models, Animal | 4 | 2020 | 18006 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2017 | 1146 | 0.030 |
Why?
|
Smoking | 2 | 2023 | 8969 | 0.030 |
Why?
|
Neutropenia | 1 | 2018 | 891 | 0.030 |
Why?
|
Exanthema | 1 | 2017 | 488 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2017 | 598 | 0.030 |
Why?
|
Codon | 1 | 2014 | 611 | 0.030 |
Why?
|
Acute Disease | 1 | 2023 | 7141 | 0.030 |
Why?
|
Monocytes | 1 | 2022 | 2593 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2016 | 678 | 0.030 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2018 | 730 | 0.030 |
Why?
|
Salivary Gland Neoplasms | 1 | 2016 | 297 | 0.030 |
Why?
|
Phenotype | 3 | 2021 | 16331 | 0.030 |
Why?
|
Receptors, Virus | 1 | 2016 | 648 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2008 | 15494 | 0.030 |
Why?
|
Genetic Linkage | 1 | 1998 | 2422 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2018 | 1181 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2017 | 2030 | 0.030 |
Why?
|
Therapies, Investigational | 1 | 2013 | 111 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2013 | 127 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2011 | 0.030 |
Why?
|
Advisory Committees | 1 | 2016 | 773 | 0.030 |
Why?
|
Lymph Node Excision | 2 | 2009 | 1248 | 0.030 |
Why?
|
Health Behavior | 1 | 2023 | 2630 | 0.030 |
Why?
|
Blood Donors | 1 | 2013 | 355 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 1799 | 0.020 |
Why?
|
Genes, MHC Class II | 2 | 1989 | 458 | 0.020 |
Why?
|
Genetic Markers | 1 | 1998 | 2633 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2017 | 1200 | 0.020 |
Why?
|
Aminolevulinic Acid | 1 | 2012 | 142 | 0.020 |
Why?
|
Biological Products | 1 | 2020 | 856 | 0.020 |
Why?
|
Societies, Medical | 2 | 2013 | 3740 | 0.020 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2013 | 337 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2018 | 2451 | 0.020 |
Why?
|
Piperidines | 1 | 2019 | 1602 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2017 | 828 | 0.020 |
Why?
|
Kidney | 2 | 2016 | 7167 | 0.020 |
Why?
|
Angiopoietin-1 | 1 | 2010 | 114 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 14720 | 0.020 |
Why?
|
Hypersensitivity, Delayed | 2 | 2003 | 485 | 0.020 |
Why?
|
Receptor, TIE-2 | 1 | 2010 | 178 | 0.020 |
Why?
|
Organ Specificity | 1 | 2015 | 2003 | 0.020 |
Why?
|
Autophagy | 1 | 2018 | 1301 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2557 | 0.020 |
Why?
|
Myeloproliferative Disorders | 1 | 2016 | 603 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1670 | 0.020 |
Why?
|
Transplantation, Autologous | 3 | 2003 | 2123 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2014 | 1792 | 0.020 |
Why?
|
Databases, Factual | 2 | 2017 | 7716 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2003 | 5019 | 0.020 |
Why?
|
Interferons | 1 | 2013 | 704 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2019 | 1788 | 0.020 |
Why?
|
Saguinus | 1 | 1988 | 17 | 0.020 |
Why?
|
Transcription Factors | 2 | 2020 | 12164 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 2935 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 4 | 2019 | 35342 | 0.020 |
Why?
|
Risk Factors | 4 | 2021 | 72145 | 0.020 |
Why?
|
Adenoviridae | 2 | 2003 | 1096 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2015 | 3847 | 0.020 |
Why?
|
Placebos | 1 | 2013 | 1677 | 0.020 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2014 | 700 | 0.020 |
Why?
|
DNA Probes | 1 | 1989 | 560 | 0.020 |
Why?
|
Monkey Diseases | 1 | 1988 | 77 | 0.020 |
Why?
|
Leukemia | 1 | 2016 | 1507 | 0.020 |
Why?
|
Gene Library | 1 | 2010 | 1076 | 0.020 |
Why?
|
Universities | 1 | 2013 | 953 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 600 | 0.020 |
Why?
|
Retroviridae Infections | 1 | 1988 | 151 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3518 | 0.020 |
Why?
|
raf Kinases | 1 | 2008 | 122 | 0.020 |
Why?
|
Photosensitizing Agents | 1 | 2012 | 602 | 0.020 |
Why?
|
Watchful Waiting | 1 | 2012 | 491 | 0.020 |
Why?
|
Epitopes, B-Lymphocyte | 1 | 2008 | 87 | 0.020 |
Why?
|
HLA-DR Antigens | 1 | 1989 | 644 | 0.020 |
Why?
|
Benzenesulfonates | 1 | 2008 | 169 | 0.020 |
Why?
|
Histocompatibility Testing | 1 | 1989 | 742 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2013 | 839 | 0.020 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2008 | 150 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2016 | 2455 | 0.020 |
Why?
|
Lung | 2 | 2016 | 9826 | 0.020 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2008 | 287 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2016 | 6382 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2016 | 19862 | 0.020 |
Why?
|
Renal Dialysis | 1 | 2016 | 1780 | 0.020 |
Why?
|
Macaca | 1 | 1988 | 440 | 0.020 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2008 | 250 | 0.020 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2006 | 57 | 0.020 |
Why?
|
Genotype | 2 | 2014 | 12946 | 0.020 |
Why?
|
Treatment Failure | 1 | 2012 | 2615 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2014 | 3557 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15994 | 0.020 |
Why?
|
Half-Life | 1 | 2007 | 658 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 1991 | 1679 | 0.020 |
Why?
|
Molecular Biology | 1 | 2009 | 595 | 0.020 |
Why?
|
Loss of Heterozygosity | 1 | 2008 | 678 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 17400 | 0.020 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 1622 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9735 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 1661 | 0.020 |
Why?
|
K562 Cells | 1 | 2007 | 632 | 0.020 |
Why?
|
Genetic Engineering | 2 | 2003 | 952 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2010 | 1875 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2005 | 228 | 0.020 |
Why?
|
International Cooperation | 1 | 2011 | 1421 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5851 | 0.020 |
Why?
|
Breast Neoplasms | 2 | 2008 | 20774 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10392 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 2003 | 1801 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2022 | 11470 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2016 | 4554 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2016 | 3465 | 0.020 |
Why?
|
Mice, SCID | 1 | 2010 | 2715 | 0.020 |
Why?
|
Skin Diseases | 1 | 2013 | 1065 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2008 | 627 | 0.010 |
Why?
|
DNA Methylation | 1 | 2018 | 4282 | 0.010 |
Why?
|
Comorbidity | 1 | 2018 | 10372 | 0.010 |
Why?
|
Health Status | 1 | 2017 | 4030 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2286 | 0.010 |
Why?
|
Interdisciplinary Communication | 1 | 2009 | 950 | 0.010 |
Why?
|
Chromosome Deletion | 1 | 2008 | 1400 | 0.010 |
Why?
|
U937 Cells | 1 | 2003 | 268 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2008 | 1284 | 0.010 |
Why?
|
Prostatic Neoplasms | 3 | 2012 | 11039 | 0.010 |
Why?
|
Registries | 1 | 2018 | 8077 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9639 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 2012 | 2458 | 0.010 |
Why?
|
Microtubule-Associated Proteins | 1 | 2008 | 1086 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2009 | 1503 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2008 | 1758 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 12071 | 0.010 |
Why?
|
Palliative Care | 1 | 2017 | 3478 | 0.010 |
Why?
|
Drug Discovery | 1 | 2009 | 1057 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3611 | 0.010 |
Why?
|
Polymorphism, Genetic | 2 | 1990 | 4328 | 0.010 |
Why?
|
Body Mass Index | 1 | 2019 | 12695 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2003 | 1581 | 0.010 |
Why?
|
Chromosome Aberrations | 1 | 2008 | 1811 | 0.010 |
Why?
|
Administration, Oral | 1 | 2008 | 3913 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2003 | 768 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18355 | 0.010 |
Why?
|
Child | 2 | 2020 | 77478 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2003 | 2837 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12220 | 0.010 |
Why?
|
Mucin-1 | 1 | 2003 | 543 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 1989 | 768 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2002 | 2257 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7153 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2013 | 13029 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2008 | 2948 | 0.010 |
Why?
|
Alternative Splicing | 1 | 2002 | 1118 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 1991 | 3915 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2002 | 1640 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 1988 | 3164 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2002 | 4322 | 0.010 |
Why?
|
Thiotepa | 1 | 1994 | 66 | 0.010 |
Why?
|
Hematopoietic Cell Growth Factors | 1 | 1994 | 102 | 0.010 |
Why?
|
Eosinophils | 1 | 1998 | 953 | 0.010 |
Why?
|
Genome, Human | 1 | 2007 | 4420 | 0.010 |
Why?
|
Physicians | 1 | 1991 | 4554 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 2005 | 2522 | 0.010 |
Why?
|
Genetic Variation | 2 | 2002 | 6540 | 0.010 |
Why?
|
Boston | 1 | 2005 | 9305 | 0.010 |
Why?
|
Blood Cells | 1 | 1994 | 309 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 1994 | 647 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2008 | 6347 | 0.010 |
Why?
|
Twins, Dizygotic | 1 | 1990 | 236 | 0.010 |
Why?
|
beta 2-Microglobulin | 1 | 1990 | 315 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1990 | 1086 | 0.010 |
Why?
|
Isoelectric Focusing | 1 | 1988 | 181 | 0.010 |
Why?
|
Saimiri | 1 | 1989 | 330 | 0.010 |
Why?
|
Chimera | 1 | 1990 | 485 | 0.010 |
Why?
|
Deltaretrovirus Infections | 1 | 1988 | 26 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 1994 | 2236 | 0.000 |
Why?
|
Precipitin Tests | 1 | 1988 | 829 | 0.000 |
Why?
|
Molecular Weight | 1 | 1990 | 2255 | 0.000 |
Why?
|
Papio | 1 | 1989 | 656 | 0.000 |
Why?
|
Nucleic Acid Hybridization | 1 | 1989 | 1374 | 0.000 |
Why?
|
Macaca fascicularis | 1 | 1989 | 908 | 0.000 |
Why?
|
Major Histocompatibility Complex | 1 | 1990 | 935 | 0.000 |
Why?
|
Retroviridae | 1 | 1988 | 914 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2002 | 21719 | 0.000 |
Why?
|
Hematopoiesis | 1 | 1994 | 2066 | 0.000 |
Why?
|
Histocompatibility Antigens Class II | 1 | 1988 | 1470 | 0.000 |
Why?
|
Macaca mulatta | 1 | 1989 | 2378 | 0.000 |
Why?
|
Hematopoietic Stem Cells | 1 | 1994 | 3381 | 0.000 |
Why?
|
Alleles | 1 | 1988 | 6931 | 0.000 |
Why?
|
DNA | 1 | 1990 | 7289 | 0.000 |
Why?
|